MedTrace Logo

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

NCT04454580 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2020-09-16

No results posted yet for this study

Summary

This is a retrospective, observational, monocentric study to evaluate the efficacy and safety of the combination of an hypomethylating agent with venetoclax newly diagnosed patients with acute myeloid leukemia ineligible for intensive chemotherapy

Conditions

  • Acute Myeloid Leukemia, Adult
  • Hypomethylating Agents
  • Venetoclax

Interventions

DRUG

Venetoclax

treatment with azacitidine or decitabine in combination with venetoclax

Sponsors & Collaborators

  • Ospedale Maggiore Di Trieste

    lead OTHER

Principal Investigators

  • Francesco Zaja, Professor · SC Ematologia Ospedale Maggiore Trieste

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2020-09-16
Completion
2020-09-30
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04454580 on ClinicalTrials.gov